1.
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
by Atkins, Michael B
The lancet oncology, 2018-03, Vol.19 (3), p.405-415
2.
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
by Roberts, Jason A, Prof
The Lancet infectious diseases, 2014, Vol.14 (6), p.498-509
3.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
by El-Khoueiry, Anthony B, Dr
The Lancet (British edition), 2017, Vol.389 (10088), p.2492-2502
4.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre...
by San-Miguel, Jesús F, Prof
The lancet oncology, 2014, Vol.15 (11), p.1195-1206
5.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
by Dimopoulos, Meletios A
The lancet oncology, 2017-10, Vol.18 (10), p.1327-1337
6.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-bl...
by Wilke, Hansjochen, Prof
The lancet oncology, 2014, Vol.15 (11), p.1224-1235
7.
Understanding dosing: children are small adults, neonates are immature children
by Anderson, Brian J
Archives of disease in childhood, 2013-09, Vol.98 (9), p.737-744
8.
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomise...
by Burmester, Gerd R, Prof
The Lancet (British edition), 2013, Vol.381 (9865), p.451-460
9.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
by Banerji, Udai, Prof
The lancet oncology, 2019, Vol.20 (8), p.1124-1135
10.
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-contro...
by Bang, Yung-Jue
The lancet oncology, 2017-12, Vol.18 (12), p.1637-1651
11.
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
by Rudin, Charles M, Prof
The lancet oncology, 2016, Vol.18 (1), p.42-51
12.
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase...
by Récher, Christian, Prof
The Lancet (British edition), 2011, Vol.378 (9806), p.1858-1867
13.
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Gr...
by Eichenauer, Dennis A
The lancet oncology, 2017-12, Vol.18 (12), p.1680-1687
14.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
by Robert, Caroline, Prof
The Lancet (British edition), 2014, Vol.384 (9948), p.1109-1117
15.
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial
by Bisogno, Gianni
The lancet oncology, 2018-08, Vol.19 (8), p.1061-1071
16.
A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain
by Doherty, Michael
Annals of the rheumatic diseases, 2011-09, Vol.70 (9), p.1534-1541
17.
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-b...
by Glund, Stephan, Dr
The Lancet (British edition), 2015, Vol.386 (9994), p.680-690
18.
Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstrea...
by Batirel, A
European journal of clinical microbiology & infectious diseases, 2014-02-15, Vol.33 (8), p.1311-1322
19.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gas...
by Doi, Toshihiko
The lancet oncology, 2017-11, Vol.18 (11), p.1512-1522
20.
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
by Vande Casteele, Niels
Gut, 2015-10, Vol.64 (10), p.1539-1545
